Deborah Doroshow, Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai, shared Fionnuala Crowley’s, Integrated Oncologist and Palliative Care Fellow at Mount Sinai Hematology, post on X, adding:
“What matters most to patients when choosing 1L treatment for EGFRmt NSCLC? What do physicians consider? Fill out our survey and you’ll earn yourself a cute pin and some high-quality chocolate from me.”
Quoting Fionnuala Crowley’s post:
“EGFR Choices is a collaborative study with EGFR Resisters asking patients with EGFR-mutated lung cancer what matters most in treatment decisions, and asking their oncologists what shapes those conversations. Oncologist survey below.”
Other articles featuring Deborah Doroshow and Fionnuala Crowley on OncoDaily.
